Patents by Inventor Ivan A. Olave

Ivan A. Olave has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heat stable vaccines
    Patent number: 11110163
    Abstract: The invention is directed to an oral vaccine composed of a micronized freeze-dried rotavirus particle suspension with buffering excipients in a non-aqueous liquid. This IVT-06 formulation has imparted heat stability by protecting the virus at temperatures of 30° C. and 40° C. for at least twelve months. Extrapolations from the 12-month stability data indicate a shelf life of more than two years at 30° C., and six months at 50° C. In addition, for ease of administration, the formulated dose has a volume of 0.5 mL.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: September 7, 2021
    Assignee: Inventprise, LLC
    Inventors: Subhash V. Kapre, Ivan A. Olave
  • Heat Stable Vaccines
    Publication number: 20200009242
    Abstract: The invention is directed to an oral vaccine composed of a micronized freeze-dried rotavirus particle suspension with buffering excipients in a non-aqueous liquid. This IVT-06 formulation has imparted heat stability by protecting the virus at temperatures of 30° C. and 40° C. for at least twelve months. Extrapolations from the 12-month stability data indicate a shelf life of more than two years at 30° C., and six months at 50° C. In addition, for ease of administration, the formulated dose has a volume of 0.5 mL.
    Type: Application
    Filed: September 16, 2019
    Publication date: January 9, 2020
    Applicant: Inventprise, LLC
    Inventors: Subhash V. Kapre, Ivan A. Olave
  • Heat stable liquid rotavirus vaccine
    Patent number: 10413604
    Abstract: The invention is directed to an oral vaccine composed of a micronized freeze-dried rotavirus particle emulsion with buffering excipients in a non-aqueous liquid. This IVT-06 formulation has imparted heat stability by protecting the virus at temperatures of 30° C. and 40° C. for at least twelve months. Extrapolations from the 12-month stability data indicate a shelf life of more than two years at 30° C., and six months at 50° C. In addition, for ease of administration, the formulated dose has a volume of 0.5 mL.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: September 17, 2019
    Assignee: Inventprise, LLC
    Inventors: Subhash V. Kapre, Ivan A. Olave